CDC Website CDC Website

To Join the NPIN community or

You are here

State Agencies

Understanding HIV Persistence in Infants (R01)

The purpose of this Funding Opportunity Announcement (FOA) is to stimulate research in the pathogenesis of perinatal HIV-1 infection by elucidating HIV-1 immune responses in the setting of the infant’s evolving immune system and mechanisms of establishment and maintenance of HIV-1 latent viral reservoirs. The goal of this FOA is to gain knowledge to be used in the future development of strategies to induce HIV-1 remission.

Mechanisms of Immune Activation and Inflammation: HIV Infection, ART, and Drugs of Abuse (R01)

The purpose of this FOA is to promote research to investigate the underlying molecular mechanisms of HIV infection-induced immune activation and inflammation in the presence of antiretroviral therapy (ART) agents and drugs of abuse. The ultimate goal is to obtain information for developing therapeutic interventions for attenuating chronic inflammation-associated comorbidities as well as for restoring or improving ART efficacy in HIV-infected drug-abusing populations.

The Role of Dysbiosis in Cardiovascular, Pulmonary and Hematological Complications During HIV Infection (R01)

The purpose of this Funding Opportunity Announcement (FOA) is to invite basic research project grant applications for HIV Microbiome Centers to perform investigations on the role of HIV-induced dysbiosis and how this imbalance may induce and/or contribute to the occurrence of heart, lung, or blood (HLB) co-morbidities in HIV positive individuals. This FOA will support mechanistic studies that will use in vitro, in vivo, ex vivo, and in silico models applied to HIV research.

Improving Hepatitis B and C Care Cascades; Focus on Increased Testing and Diagnosis

CDC will provide funds to states and limited local Health Departments to work in collaboration with external partners throughout the health care system, and other stakeholders as relevant, to 1) conduct a situational analysis in their jurisdiction to include a) number and description of clinical and other settings that can provide CDC/USPSTF recommended testing and linkages to care and treatment services related to hepatitisC virus (HCV) and hepatitis B virus (HBV) testing and, b) based on this analysis, assess the quality of current HCV and HBV testing and detection activities in each sett

Resilient and Responsive Health Systems (RRHS) Initiative

Supported through the President’s Emergency Plan for AIDS Relief (PEPFAR), the Health Resources and Services Administration (HRSA) HIV/AIDS Bureau (HAB) is accepting applications for fiscal year (FY) 2017 in support of the Resilient and Responsive Health Systems (RRHS) Initiative. The purpose of this initiative is to address fundamental health systems constraints that impede the availability of and access to quality health services related to HIV, other infectious diseases and priority health areas in the Democratic Republic of Congo (DRC), Liberia, Sierra Leone, and South Sudan.

Silencing of HIV-1 Proviruses (R61/R33)

This Funding Opportunity Announcement (FOA) encourages Exploratory and developmental bi-phasic research applications to support the identification and optimization of small molecules or RNAs that interact with host epigenetic machinery to mediate long-term or permanent epigenetic silencing of HIV-1 proviruses.

Limited Interaction Targeted Epidemiology (LITE) to Advance HIV Prevention (UG3/UH3)

The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications to use innovative technology to conduct epidemiologic studies of large cohorts of U.S. populations at high risk of HIV infection: men who have sex with men (MSM), transgender women, and black/African American women. The UG3/UH3 Phased Innovation Awards Cooperative Agreement involves 2 phases. Funding for a UG3 phase will be used to enroll and follow sufficient numbers of high-risk HIV-negative participants to reach seroconversion milestone targets.

Sustained Release of Antivirals for Treatment or Prevention of HIV (SRATP) (R01)

The purpose of this Funding Opportunity Announcement (FOA) is to encourage grant applications that address the long term goal and objective of developing sustained release strategies for HIV treatment or prevention. Applications may propose treatment or prevention products delivered using sustained release platforms (oral, injection, implant or direct delivery to HIV target mucosa) that will provide a minimum of 1 week for oral (treatment) or a minimum of once a month for all other drug delivery systems for prevention and treatment protection/efficacy.

Pages

Subscribe to RSS - State Agencies